Volume 125, Issue 12 pp. 2893-2902
Early Detection and Diagnosis

Active MMP-2 effectively identifies the presence of colorectal cancer

Mary Jo Murnane

Corresponding Author

Mary Jo Murnane

Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA

Department of Biochemistry, Boston University School of Medicine, Boston, MA

Fax: 617-414-7073.

Department of Pathology and Laboratory Medicine, Boston University School of Medicine, 670 Albany St--4th floor, Boston, 02118 MASearch for more papers by this author
Jinguo Cai

Jinguo Cai

Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA

Search for more papers by this author
Sania Shuja

Sania Shuja

Department of Pathology, University of Florida College of Medicine, Jacksonville, FL

Search for more papers by this author
David McAneny

David McAneny

Department of Surgery, Boston University School of Medicine, Boston, MA

Search for more papers by this author
Veronica Klepeis

Veronica Klepeis

Department of Pathology, Massachusetts General Hospital, Boston, MA

Search for more papers by this author
John B. Willett

John B. Willett

Graduate School of Education, Harvard University, Cambridge, MA

Search for more papers by this author
First published: 23 June 2009
Citations: 42

Abstract

Fully active MMP-2 is expressed at such low levels in human tissues that studies often fail to confirm its value as a cancer marker despite strong associations with malignancy. Our study utilized careful extraction, accurate activity measurements, standardization to purified controls and a new statistical metric to determine whether active MMP-2 is an effective indicator of colorectal cancer compared to pro-MMP-2 or pro-MMP-9. MMP-2 and MMP-9 activities were analyzed in matched normal and cancer samples from 269 patients by gelatin zymography, computer-assisted image analysis, serial dilutions of strong samples and standardization to controls. An index of effect size was designed for comparative evaluation of active MMP-2, pro-MMP-2 and pro-MMP-9 activities. For each gelatinase, mean activity and protein levels/mg soluble protein in normal mucosa and colorectal cancer were calculated for the first time with respect to commercial standards. Active MMP-2 activity, detected in 99% of colorectal cancers, was higher in 95% of cancers (on average 10-fold) than in normal mucosa. Levels of pro-MMP-2 and pro-MMP-9, but not active MMP-9, activities were also significantly higher in cancers versus normal. However, active MMP-2 activity provided the most effective test for the presence of cancer (p < 0.0.0001) with an effect size statistically significantly larger than for either pro-MMP-2 or pro-MMP-9. Receiver operating characteristic (ROC) curves demonstrated that a cut-off for active MMP-2 of >44 SDU activity/mg soluble protein (>180 pg/mg), which is three times mean normal levels, would permit detection of colorectal cancer with an estimated sensitivity of 84% and estimated specificity of 93%. © 2009 UICC

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.